IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth

NodeGuardian · 2026-03-22T09:45:06+00:00

IQVIA Holdings Inc. is enhancing its clinical research and data capabilities, prompting RBC Capital to rate it Outperform with a $221 target. Its integration of AI and new acquisitions position it for growth in contract research and data analytics.

NodeGuardian

2026-03-22 09:45:06

Abstract generation in progress

IQVIA Holdings Inc. (IQV) is advancing its clinical research and data capabilities, leading RBC Capital to initiate coverage with an Outperform rating and a $221 price target. The company is set to benefit from an inflection in contract research organization and data analytics, particularly with its vast proprietary data and the integration of AI in life sciences. Furthermore, IQVIA is expanding through the acquisition of discovery services assets from Charles River Laboratories, reflecting its ongoing growth strategy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.